LABCENTRAL, BIOLABS, MBC BIOLABS PARTNER WITH EVOTEC TO SUPPORT
BIOTECH INNOVATORS THROUGH CRITICAL INFLECTION POINTS
AGREEMENT LEVERAGES EVOTEC’S INTEGRATED END-TO-END SHARED R&D
PLATFORM TO ENABLE GREATER ACCESS TO INDUSTRY-GRADE CAPABILITIES AND
DRUG HUNTING EXPERTISE FOR LIFE SCIENCES AND BIOTECH STARTUPS ACROSS
THE GLOBAL LABCENTRAL / BIOLABS / MBC BIOLABS NETWORK
ALL PARTIES PLAY SYNERGISTIC ROLES IN SUPPORTING AND FOSTERING THE
SHARED R&D ECONOMY INNOVATION ECOSYSTEM
Hamburg, Germany, and Cambridge, Mass., USA, 27 September 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;
NASDAQ: EVO), LabCentral, a launchpad for high-potential life science and biotech
start-ups, BioLabs, an international membership based network of shared lab and
office facilities, and MBC BioLabs, premier providers of co-working laboratory space,
today announced an agreement to boost early-stage innovations through access to
Evotec’s leading shared end-to-end R&D platform.
The agreement will empower LabCentral / BioLabs / MBC BioLabs’s network of
promising early-stage life science and biotech companies by enhanced access to
Evotec’s industry-leading, innovative end-to-end platform and latest technologies for
successful drug discovery and development to translate innovative life science
research into new, improved ways to treat patients. Through this partnership,
Evotec’s team of scientists, business builders and experts will have regular presence
on-site across the LabCentral / BioLabs / MBC BioLabs network in the form of hosted
educational events and office hours – parts of the efforts towards the joint goal of
enhancing success rates of the early-stage companies in the ecosystem.
LabCentral / BioLabs / MBC BioLabs offers laboratory and office spaces for over 400
start-ups comprising approximately 3,500 scientists and entrepreneurs, giving Evotec
direct access to promising research of biotech companies across the US, France and
Germany.
Dr Matthias Evers, Chief Business Officer of Evotec, commented: “The
collaboration with LabCentral / BioLabs / MBC BioLabs is closely aligned with our
mission ‘Together for Medicines that Matter’. Providing innovators across a globally
recognized life science & biotech network access to our industry-leading end-to-end
R&D platform enabling speed, safety, efficiency, and enhanced probabilities of
success from bench to bedside, will allow more opportunities to discover and develop
life-saving therapies.”
Dr Johannes Fruehauf, Founder and President of BioLabs and
LabCentral added: “As a strategic partner across the network of LabCentral and
BioLabs facilities, Evotec’s R&D platform will help our residents accelerate their
research as we collectively align on a mission to discover and develop new drugs and
therapies to improve human health faster, more efficiently and on a global scale.”
Dr Robert Blazej, Director of MBC BioLabs, expressed his excitement
about the partnership, stating: “We are thrilled to bring Evotec’s world-leading
R&D platform even closer to the companies operating in our San Francisco Bay Area
facilities. Our goal has always been to empower brilliant entrepreneurs within a
thriving ecosystem that fosters innovation, collaboration, and ultimately, success.
Evotec’s shared R&D platform dovetails with our shared lab co-working space,
furthering this mission.”
No financial terms of the agreement were disclosed.
ABOUT LABCENTRAL
A private, non-profit institution, LabCentral was founded in 2013 as a launchpad for high potential life-
sciences and biotech startups. Operating a total of 225,000 square-feet in the heart of Kendall Square
in Cambridge, Mass., LabCentral offers fully permitted laboratory and office space for as many as 100
startups comprising approximately 1,000 scientists and entrepreneurs. More information is available
ABOUT BIOLABS
BioLabs is the definitive growth partner for science-based entrepreneurs, empowering companies to
accelerate their science, grow their business, and have a lasting impact on the world. The BioLabs
difference is in their sector-defining ecosystem: delivering best-in-class lab space, essential business
services, a powerful network of innovators and guides who offer “been-there” insight, and site teams with
unparalleled experience guiding founders through the operational complexities of growing a biotech
company. BioLabs centers are located in key innovation hubs across North America, Europe, and now
expanding to Japan.
ABOUT MBC BIOLABS
MBC BioLabs is a premier life science incubator that provides early-stage biotech companies with the
resources and support necessary to thrive. Through its network of state-of-the-art laboratories, industry
partnerships, and engaged bioentrepreneur community, MBC BioLabs empowers startups to accelerate
their research and propel groundbreaking ideas into transformative therapies. Since opening in 2013, MBC BioLabs has helped launch and grow 290 companies. These companies have brought 153 programs to the clinic, produced 17 approved diagnostics, and raised over $13 billion.
ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover
and develop highly effective therapeutics and make them available to the patients. The Company’s
multimodality platform comprises a unique combination of innovative technologies, data and science
for the discovery, development, and production of first-in-class and best-in-class pharmaceutical
products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and
within a network of partners including all Top 20 Pharma and over 800 biotechnology companies,
academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a
broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well
as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-
leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more
than 200 proprietary and co-owned R&D projects from early discovery to clinical development.
Evotec operates globally with more than 5,000 highly qualified people. The Company’s 17 sites offer
highly synergistic technologies and services and operate as complementary clusters of excellence.
For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and
FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the
proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and
variations of such words and similar expressions are intended to identify forward-looking
statements. Such statements include comments regarding Evotec’s expectations for revenues, Group
EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the
information available to, and the expectations and assumptions deemed reasonable by Evotec at the
time these statements were made. No assurance can be given that such expectations will prove to
have been correct. These statements involve known and unknown risks and are based upon a
number of assumptions and estimates, which are inherently subject to significant uncertainties and
contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any
obligations or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Evotec’s expectations with respect thereto or
any change in events, conditions or circumstances on which any statement is based.